Get the Stockscreener App
9.81
11.22%
-1.24
After Hours:
9.87
0.06
+0.61%
Yd Bio Ltd stock is traded at $9.81, with a volume of 53,541.
It is down -11.22% in the last 24 hours and down -17.01% over the past month.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
See More
Previous Close:
$11.05
Open:
$11.2
24h Volume:
53,541
Relative Volume:
0.77
Market Cap:
$691.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.83%
1M Performance:
-17.01%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.76
$11.27
1-Week Range:
$9.76
$11.80
52-Week Range:
$7.90
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
9.81 | 779.26M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Yd Bio Ltd Stock (YDES) Latest News
CMB.TECH to Release Q4 2025 Earnings on February 26, 2026 - Intellectia AI
CMB.TECH Sells Two VLCCs, Realizing $98.2 Million Gain - Intellectia AI
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million By Investing.com - Investing.com Nigeria
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal By Investing.com - Investing.com South Africa
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal - Investing.com Canada
YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership - Nasdaq
YD Bio enters into binding LOI to acquire shares, assets of SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million - Investing.com
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy - The Manila Times
Cancer detection firm YD Bio targets $26.87M glioblastoma cell therapy deal - stocktitan.net
Diabetic Macular Edema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotech - Barchart.com
YD Bio Limited Announces Directorate Changes - marketscreener.com
YDES Stock Price, News & Analysis - Stock Titan
YD Bio Limited (YDES) board reshaped by majority holders’ written consent - Stock Titan
YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Research Tree
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal - Investing.com Australia
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal By Investing.com - Investing.com South Africa
How an AI cancer test in Taipei hospitals could help shape future drugs - Stock Titan
YD Bio Limited entered into a Memorandum of Understanding to acquire EG BioMed Co., Ltd. - MarketScreener
YD Bio advances cancer detection and eye disease platforms By Investing.com - Investing.com Australia
YD Bio LtdPlans to evaluate up to three acquisitions in 2026 - marketscreener.com
Yd Bio LtdPlans To Evaluate Up To Three Acquisitions In 2026 - TradingView — Track All Markets
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - Yahoo Finance
Micron and Lam Research among market cap stock movers on Tuesday By Investing.com - Investing.com India
YD Bio Limited Warrants (YDESW) Competitors - Meyka
YD Bio to establish California operations center for diagnostic development By Investing.com - Investing.com Australia
YD Bio to establish California operations center for diagnostic development - Investing.com India
YD Bio (Nasdaq: YDES) plans Calif. ops center for U.S. diagnostics - Stock Titan
Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound - simplywall.st
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN - Finviz
YD Bio expands cancer detection platform to pancreatic and colorectal cancers - Investing.com Australia
YD Bio expands cancer detection platform to pancreatic and colorectal cancers By Investing.com - Investing.com South Africa
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection - Yahoo Finance
YD Bio (Nasdaq: YDES) widens OkaiDx to 44 states, shows 93.8% early pancreatic sensitivity - Stock Titan
YD Bio Limited (YDESW) stock historical prices and data - Yahoo Finance UK
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday - Benzinga
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Tesla, Micron among market cap stock movers on Monday By Investing.com - Investing.com Australia
YD Bio stock rises after FDA clearance for eye care products - Investing.com Nigeria
YD Bio Stock Rises On Entry Into US Eye Care Segment - MSN
YD Bio receives FDA clearance for contact lenses and artificial tears - Investing.com India
Kyivstar Launches Starlink Direct to Cell Satellite Connectivity in Ukraine - The Manila Times
OMG Announces 28th Edition of Journal of Innovation - The Manila Times
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics - Yahoo Finance
YD Bio Limited (YDESW) Stock Historical Prices & Data - Yahoo! Finance Canada
YD Bio Limited (YDESW) company profile and facts - Yahoo Finance UK
[424B3] YD Bio Ltd Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
[6-K] YD Bio Ltd Current Report (Foreign Issuer) | YDES SEC FilingForm 6-K - Stock Titan
Yd Bio Ltd Stock (YDES) Financials Data
There is no financial data for Yd Bio Ltd (YDES). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):